Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, September 27, 2017
Crown Bioscience announced the appointment of Laurie Heilmann as Chief Business Officer.
read more
Wednesday, January 13, 2016
Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has announced the appointment of Eric Murphy, Ph.D., as global scientific director for ...
read more
Crown Bioscience announced the appointment of Dr. Leon Hall as Vice President of Global Scientific Excellence.
read more
Wednesday, September 17, 2025
Crown Bioscience announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, ...
read more
Crown Bioscience, Inc., a leading global drug discovery and development service company, today announced its HuPrime® PDX (Patient-Derived Xenograft) model collection has now passed the 1,000 individual models mark.
read more
Tuesday, January 20, 2026
Crown Bioscience announced that its San Diego laboratory has achieved College of American Pathologists (CAP) accreditation. This milestone builds on the site’s Clinical Laboratory Improvement Amendments (CLIA) certification, obtained in July 2025, ...
read more
Crown Bioscience has announced the strengthening of its global Immuno-Oncology Platform at all its key facilities in Europe, USA, and Asia to support client’s needs with a comprehensive collection of validated models and services for in vivo ...
read more
Thursday, February 11, 2016
Crown Bioscience Inc. has reached an agreement with UK’s University of York to exclusively license and commercialize the university’s unique collection of patient-derived xenograft (PDX) models for prostate cancer.
read more
Crown Bioscience announced a licensing agreement with Charles River International Research Models and Services business.
read more
Wednesday, November 29, 2017
Crown Bioscience and DSI announced the successful development of an enhanced method for preclinical obesity and type 2 diabetes studies in partnership.
read more
Crown Bioscience announced the appointment of Jean-Pierre Wery, PhD as executive chairman of the board effective immediately.
read more
Tuesday, October 10, 2017
Protea Biosciences announced it plans to develop clinical screening assays in various areas of oncology.
read more
Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre ...
read more
Wednesday, March 14, 2018
Crown Bioscience has been selected by Phanes Therapeutics as a strategic partner to advance their oncology drug discovery pipeline.
read more
Crown Bioscience announced the launch of pre-clinical models of IBD and RA to help inform decision making in pre-clinical drug development.
read more